Zobrazeno 1 - 10 of 13 pro vyhledávání: '"Hypolipidemic Agents/*adverse effects"'
1
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
Autor: Fruchart, J.C., Santos, R.D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P.J., Ceska, R., Corsini, A., Després, J.P., Duriez, P., Eckel, R.H., Ezhov, M.V., Farnier, M., Ginsberg, H.N., Hermans, M.P., Ishibashi, S., Karpe, F., Kodama, T., Koenig, W., Krempf, M., Lim, S., Lorenzatti, A.J., McPherson, R., Nuñez-Cortes, J.M., Nordestgaard, B.G., Ogawa, H., Packard, C.J., Plutzky, J., Ponte-Negretti, C.I., Pradhan, A., Ray, K.K., Reiner, Ž., Ridker, P.M., Ruscica, M., Sadikot, S., Shimano, H., Sritara, P., Stock, J.K., Su, T.C., Susekov, A.V., Tartar, A., Taskinen, M.R., Tenenbaum, A., Tokgözoğlu, L.S., Tomlinson, B., Tybjærg-Hansen, A., Valensi, P., Vrablík, M., Wahli, W., Watts, G.F., Yamashita, S., Yokote, K., Zambon, A., Libby, P.
Publikováno v: Cardiovascular diabetology, vol. 18, no. 1, pp. 71
In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::1e42e4b07a96300e14b1450540aec81b
https://serval.unil.ch/resource/serval:BIB_A62033B5071E.P001/REF.pdf
Zobrazit plný text záznamu
2
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Autor: Jean-Pierre Zarski, Raoul Poupon, Christine Silvain, Victor de Ledinghen, Dominique Rainteau, Sylvie Chollet-Martin, Fabien Zoulim, Odile Goria, Armand Abergel, Gisèle N'Kontchou, Pascal Potier, François Habersetzer, Guillaume Lefèvre, Anne Minello, Farid Gaouar, Olivier Roux, Eric Nguyen-Khac, Olivier Chazouillères, Jérôme Boursier, Lydie Humbert, Jean-Pierre Bronowicki, Isabelle Ollivier-Hourmand, Sara Lemoinne, Maryline Debette-Gratien, Dominique Larrey, Christophe Corpechot, Luc de Chaisemartin, Philippe Mathurin, Alexandra Rousseau, Alexandra Heurgué-Berlot, Farid-Hakeem Admane, Tabassome Simon, Antonia Le Gruyer
Publikováno v: The New England Journal of Medicine
The New England Journal of Medicine, 2018, 378 (23), pp.2171-2181. ⟨10.1056/NEJMoa1714519⟩
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2018, 378 (23), pp.2171-2181. ⟨10.1056/NEJMoa1714519⟩
IF 79.258 (2017); International audience; Background : Patients with primary biliary cholangitis who have an inadequate response to therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which are agonists of peroxisome
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43a3a9626c84bdc35937db40fb31d648
https://hal.archives-ouvertes.fr/hal-02460238
Zobrazit plný text záznamu
3
New evidence for nicotinic acid treatment to reduce atherosclerosis
Autor: Alessandra Quercioli, Fabrizio Montecucco, François Mach, Franco Dallegri, Giorgio Luciano Viviani
Publikováno v: Expert Review of Cardiovascular Therapy
Expert Review of Cardiovascular Therapy, Vol. 8, No 10 (2010) pp. 1457-1467
Expert Review of Cardiovascular Therapy; Vol 8
Nicotinic acid (at a daily dose of grams) has been shown to induce potent anti-atherosclerotic effects in human and animal models. Evidence from clinical studies performed in the 1950s has shown that nicotinic acid treatment remarkably improves the p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f455469e66f66a9c0e12a2e4be51ab8e
https://pubmed.ncbi.nlm.nih.gov/20936932
Zobrazit plný text záznamu
5
Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose
Autor: Kostapanos, M. S., Milionis, H. J., Agouridis, A. D., Rizos, C. V., Elisaf, M. S.
AIM OF THE STUDY: The increase in physician-reported diabetes following rosuvastatin treatment in the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin study has raised concerns whether this statin exer
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10561::97df3b238ee11de7861f0786330cbd08
http://olympias.lib.uoi.gr/jspui/handle/123456789/18489
Zobrazit plný text záznamu
6
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia
Autor: Kostapanos, M. S., Milionis, H. J., Filippatos, T. D., Nakou, E. S., Bairaktari, E. T., Tselepis, A. D., Elisaf, M. S.
BACKGROUND: Although the effect of statins on lowering low-density lipoprotein cholesterol (LDL-C) has been extensively studied, their hypotriglyceridemic capacity is not fully understood. OBJECTIVE: The present study examined clinical and laboratory
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10561::667d7551c286c71e1be80613bb54f3b7
http://olympias.lib.uoi.gr/jspui/handle/123456789/24406
Zobrazit plný text záznamu
9
Effects of fibrates on serum metabolic parameters
Autor: Elisaf, M. S.
Fibric acid derivatives are a class of hypolipidaemic drugs used in the treatment of patients with hypertriglyceridaemia, mixed hyperlipidaemia and diabetic dyslipidaemia. Fibrate therapy results in a significant decrease in serum triglycerides and a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10561::7ca7a374dfa292a8cf3d765bafd8194e
http://olympias.lib.uoi.gr/jspui/handle/123456789/22092
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje